Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Snap On Incorporated — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Snap On Incorporated trades at $365.17 (market cap $18.80B). The key difference: Snap On Incorporated is far larger — about 19.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Snap On Incorporated pays a 2.68% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Snap On Incorporated for 38 Days on average.
| MRVI | SNA | |
|---|---|---|
Market Cap | $977.37M | $18.80B |
Volume | 2,742,564 | 214,829 |
Sector | Health | Industrials |
52-Week High | $9.00 | $419.31 |
52-Week Low | $2.83 | $328.69 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $1.08B | $18.44B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Snap-On Incorporated (SNA) trades at $363.67, up 0.46% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 19.6% and ROE of 17.58%, while Q2 2026 earnings beat estimates. Recent news highlights gross margin expansion and institutional trading activity.
The outlook is supported by analyst consensus with a $449 price target and 66.7% buy ratings, but risks include valuation premiums and mixed segment trends. Earnings growth and RCI initiatives remain key catalysts, though integration costs and softer OEM demand pose near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
